Taken together, these results indicate that combining tigecycline use and autophagy inhibition could be an effective approach in CML treatment, especially since the synergistic effect of the two drugs was still observed irrespective of the ABL tyrosine kinase point mutation status of the cells. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.